Location History:
- Koebenhavn, DK (2016)
- Koebenhavn V, DK (2018 - 2022)
Company Filing History:
Years Active: 2016-2022
Title: Helle Heibroch Petersen: Innovator in Antibody Development
Introduction
Helle Heibroch Petersen is a notable inventor based in Koebenhavn V, Denmark. She has made significant contributions to the field of biomedicine, particularly in the development of innovative antibodies. With a total of 6 patents to her name, her work focuses on enhancing thrombin generation through bispecific antibodies.
Latest Patents
One of her latest patents is titled "Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)." This application discloses bispecific TFPI antibodies that can specifically and simultaneously bind two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralizing TFPI, even when the concentration of TFPI is elevated. These antibodies or compositions comprising them may be used for treating subjects with coagulopathy. Another significant patent is "Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor." This application reveals a combination of two monospecific TFPI antibodies, where one antibody binds specifically to TFPI (1-181) and the other binds to TFPI (182-276). Both the combination of these monospecific antibodies and the derived bispecific antibody significantly enhance thrombin generation by neutralizing full-length TFPIα, even at abnormally elevated concentrations of TFPI.
Career Highlights
Helle Heibroch Petersen is currently associated with Novo Nordisk A/S, a leading global healthcare company. Her work at Novo Nordisk has been pivotal in advancing therapeutic options for patients with coagulation disorders.
Collaborations
She collaborates with talented coworkers, including Ida Hilden and Berit Olsen Krogh, who contribute to her innovative research and development efforts.
Conclusion
Helle Heibroch Petersen's contributions to antibody development are noteworthy and have the potential to significantly impact the treatment of coagulopathies. Her innovative work continues to pave the way for advancements in biomedicine.